LAS VEGAS — Visus Therapeutics completed one clinical trial for Brimochol PF, a once-daily drop for presbyopia, earlier this year and is currently enrolling patients for a second trial, a company executive said at Vision Expo West.
Visus CEO Ben Bergo told Healio that the preservative-free combination of carbachol and brimonidine outperformed both carbachol and brimonidine alone, “with approximately 50% of subjects recording a 20/40 or better improvement in their near vision out at 10 hours” in BRIO-I.
Bergo said the company anticipates “reaching full enrollment [for